Overview

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Status:
Terminated

Trial end date:
2020-09-09

Target enrollment:

Participant gender:

Summary

This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib